Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2018-01-02 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于使用闲置募集资金进行结构性存款的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 特一药业集团股份有限公司 regarding the use of idle raised funds to purchase structured deposits (financial products) from banks. It details the amounts, product types, terms, risks, and compliance measures related to these investments. The document is an announcement about the company's capital management activities, specifically the use of idle raised funds for cash management through structured deposits. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report like an Annual Report, Interim Report, or Earnings Release. It is also not a regulatory certification or voting result. The document fits best into the category of Capital/Financing Update (CAP), as it updates on the company's financing activities and capital usage related to idle raised funds and structured deposits.
2018-01-02 Chinese
关于全资子公司完成注册资本工商变更登记的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of registration capital changes for wholly-owned subsidiaries of the company. It details the board meeting approval for capital increases and the subsequent completion of registration and business license updates. The document is short (951 characters) and serves as a formal notification of a corporate action related to capital changes, but it does not contain financial statements or detailed financial analysis. It is not a full financial report, earnings release, or management discussion. It fits best as a Capital/Financing Update (CAP) because it informs about changes in registered capital and capital structure of subsidiaries.
2017-12-27 Chinese
关于签署募集资金三方及四方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 特一药业集团股份有限公司 regarding the signing of three-party and four-party supervision agreements related to the management and use of funds raised through a convertible bond issuance. It details the approval by the China Securities Regulatory Commission, the amount raised, the specific projects funded, and the establishment of special accounts for fund management. The document includes descriptions of the agreements' terms and the roles of involved parties such as the company, banks, and the sponsoring securities firm. There are no financial statements or detailed financial performance data presented; rather, it is a regulatory announcement about the governance and oversight of the raised capital. The document length is about 5,322 characters, which is relatively short and focused on the announcement of agreements rather than a full financial report. Therefore, it fits best under Capital/Financing Update (CAP), as it concerns fundraising activities and capital management updates.
2017-12-27 Chinese
关于使用闲置募集资金进行结构性存款的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company regarding the use of idle raised funds to purchase structured deposits (financial products). It details the decision made by the board, the product specifics, risk considerations, and compliance with regulatory requirements. The document does not contain financial statements or comprehensive financial data, nor is it a report like an annual or interim report. It is a specific announcement about capital management activities related to fundraising proceeds. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 2543 characters, which is consistent with an announcement rather than a full report.
2017-12-27 Chinese
关于使用闲置募集资金购买银行理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company regarding the use of idle raised funds to purchase bank wealth management products. It details the decision made by the board, the product purchased, contract terms, risks, and impact on company operations. The document is relatively short (3429 characters) and is focused on a specific financing activity involving the use of idle raised funds. It is not a full financial report, audit, or earnings release. It is not a regulatory certification or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it relates to the company's financing activities and capital management.
2017-12-25 Chinese
可转换公司债券上市公告书
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市公告书" which translates to "Listing Announcement" or "Listing Prospectus" for convertible bonds issued by TEYI Pharmaceutical Group Co., Ltd. It contains detailed information about the issuance, listing, underwriting, credit rating, and company background related to the convertible bonds. The document is issued in compliance with Chinese securities laws and regulations and is intended to announce the listing of the convertible bonds on the Shenzhen Stock Exchange. It is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a formal announcement related to capital market activity, specifically the listing of convertible bonds. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2017-12-25 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.